Table 5.

Multivariate risk factor analysis for 1-year TRM




No.

No. events, 1-year TRM

Hazard ratio

95% CI

P
Age      
   ≤ 40 y   58   15   1.0    
   > 40 y   111   38   2.2   1.1-4.0   .02  
Stage at transplantation      
   Early/intermediate   95   27   1.0    
   Advanced   74   26   1.3   0.7-2.2   NS  
Donor type      .001* 
   HLA-identical sibling   78   20   1.0    
   Unrelated   87   29   1.7   0.9-3.2   NS  
   HLA-DfRel   4   4   10.7   3.4-33.3   .000  
NOD2/CARD15      .000* 
   Wild type   119   26   1.0    
   R pos   22   10   2.4   1.1-5.0   .02  
   D pos   16   9   2.5   1.2-5.4   .02  
   R&D pos
 
12
 
8
 
6.0
 
2.6-14.1
 
.001
 



No.

No. events, 1-year TRM

Hazard ratio

95% CI

P
Age      
   ≤ 40 y   58   15   1.0    
   > 40 y   111   38   2.2   1.1-4.0   .02  
Stage at transplantation      
   Early/intermediate   95   27   1.0    
   Advanced   74   26   1.3   0.7-2.2   NS  
Donor type      .001* 
   HLA-identical sibling   78   20   1.0    
   Unrelated   87   29   1.7   0.9-3.2   NS  
   HLA-DfRel   4   4   10.7   3.4-33.3   .000  
NOD2/CARD15      .000* 
   Wild type   119   26   1.0    
   R pos   22   10   2.4   1.1-5.0   .02  
   D pos   16   9   2.5   1.2-5.4   .02  
   R&D pos
 
12
 
8
 
6.0
 
2.6-14.1
 
.001
 

Relevant patient and donor pretransplantation characteristics were compared with NOD2/CARD15 mutations in recipients (R pos), donors (D pos), and both recipients and donors (R&D pos).

HLA-DfRel indicates that the donor is a one-HLA-antigen-different relative.

*

Overall, or global, P value

or Create an Account

Close Modal
Close Modal